ESSA Pharma Inc Share Price Toronto S.E.
Equities
EPI
CA29668H1047
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 36Cr 27Cr 2.21TCr |
---|---|---|---|---|---|
Net income 2024 * | -4.8Cr -3.53Cr -294.33Cr | Net income 2025 * | -7.3Cr -5.37Cr -447.63Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.05
x | P/E ratio 2025 * |
-5.91
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.72% |
Latest transcript on ESSA Pharma Inc
Managers | Title | Age | Since |
---|---|---|---|
David Parkinson
CEO | Chief Executive Officer | 73 | 24/15/24 |
David Wood
DFI | Director of Finance/CFO | 66 | 01/13/01 |
Peter Virsik
COO | Chief Operating Officer | - | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 05/15/05 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 31/19/31 |
Richard Glickman
CHM | Chairman | 65 | 01/10/01 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 4.92TCr | |
+1.00% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.68% | 2.61TCr | |
-22.99% | 1.87TCr | |
+8.22% | 1.33TCr | |
+32.41% | 1.23TCr | |
-1.62% | 1.2TCr |